Form 8-K - Current report:
SEC Accession No. 0001641172-25-021552
Filing Date
2025-07-30
Accepted
2025-07-30 16:21:34
Documents
16
Period of Report
2025-07-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 43597
2 EX-99.1 ex99-1.htm EX-99.1 15039
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3898
  Complete submission text file 0001641172-25-021552.txt   275975

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ptix-20250718.xsd EX-101.SCH 3499
5 XBRL DEFINITION FILE ptix-20250718_def.xml EX-101.DEF 26527
6 XBRL LABEL FILE ptix-20250718_lab.xml EX-101.LAB 36469
7 XBRL PRESENTATION FILE ptix-20250718_pre.xml EX-101.PRE 25151
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5429
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 251167389
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)